Review
Biochemistry & Molecular Biology
Lucile Pabst, Sebastien Lopes, Basil Bertrand, Quentin Creusot, Maria Kotovskaya, Erwan Pencreach, Michele Beau-Faller, Celine Mascaux
Summary: The therapeutic algorithm for lung cancer has been revolutionized by immune checkpoint inhibitors, but the response rate and adverse events remain a challenge. Predictive and prognostic biomarkers are needed to select patients who will respond to treatment. Currently, PD-L1 expression is the only validated biomarker, but its predictive value is imperfect. New molecular features, such as tumor mutational burden, have shown promise in predicting response to immunotherapy. This review summarizes the latest knowledge on predictive and prognostic biomarkers to advance precision immuno-oncology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Qiaorui Tan, Sha Yin, Dongdong Zhou, Yajing Chi, Xiaochu Man, Huihui Li
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis and limited effective treatment options. Immunotherapy based on immune checkpoint inhibition shows promise, but its efficacy varies among TNBC patients. Therefore, identifying predictive biomarkers for immunotherapy response is crucial.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Oluwaseyi Adeuyan, Emily R. Gordon, Divya Kenchappa, Yadriel Bracero, Ajay Singh, Gerardo Espinoza, Larisa J. Geskin, Yvonne M. Saenger
Summary: The approval of immunotherapy for stage II-IV melanoma has highlighted the need for improved immune-based predictive and prognostic biomarkers. Several techniques are currently under investigation for the detection of prognostic and predictive immune biomarkers in melanoma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Immunology
Nana Wang, Abiyasi Nanding, Xiaocan Jia, Yuping Wang, Chaojun Yang, Jingwen Fan, Ani Dong, Guowei Zheng, Jiaxin Ma, Xuezhong Shi, Yongli Yang
Summary: This study comprehensively assessed the tumor immune microenvironment (TIME) of cervical cancer (CC) and constructed an ICSs prognostic model, which provides an effective tool for predicting patient's prognosis and accurate immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Yufei Xu, Fengli Zuo, Huiling Wang, Jing Jing, Xiujing He
Summary: ICB therapy has significantly changed the landscape of anticancer therapy, but only a subset of patients benefit from it and immune-related adverse events (irAEs) can occur. Finding predictive biomarkers to optimize patient outcomes and reduce toxicity risk is urgently needed. This review discusses current predictive and prognostic biomarkers for checkpoint immunotherapy in ovarian cancer (OC) and highlights emerging biomarkers to guide treatment with ICB.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, Federica Borea, Marta Aliprandi, Armando Santoro, Paolo Andrea Zucali
Summary: Malignant mesothelioma (MM) is a rare and aggressive cancer with a poor prognosis. Platinum and pemetrexed chemotherapy is currently the standard treatment for unresectable disease, but there is a lack of approved treatments for subsequent lines. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown promising results in both first line and second-third line settings for MM. However, there is a need for reliable biomarkers to improve patient selection, and various factors including histological subtype, PD-L1 expression, and tumor mutational burden have been studied with inconclusive results. Further research is needed to identify predictive biomarkers for immunotherapy in MM.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Yongqing Liu, Pengbo Hu, Liang Xu, Xiuyuan Zhang, Zhou Li, Yiming Li, Hong Qiu
Summary: The landscape of gastric cancer treatment has changed due to the use of immune checkpoint inhibitors, but only a subset of patients have benefited significantly. The identification of effective biomarkers for immunotherapy is an important research topic. This review presents a summary of predictive biomarkers that have been recently studied in clinical research.
Article
Oncology
Zhenghang Wang, Qi Zhang, Changsong Qi, Yuezong Bai, Feilong Zhao, Hui Chen, Zhongwu Li, Xicheng Wang, Mifen Chen, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Lin Shen, Jian Li
Summary: AKT1 and CDH1 mutations were identified as independent predictors of poor progression-free survival (PFS) and primary resistance to ICIs in dMMR/MSI-H GI cancer. The combination of these two genes as an immuno-oncology therapy predictor (IOpred) showed a high positive predictive value (PPV) and good performance in predicting primary resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Chun Chau Lawrence Cheung, Yong Hock Justin Seah, Juntao Fang, Nicole Hyacinth Calpatura Orpilla, Mai Chan Lau, Chun Jye Lim, Xinru Lim, Justina Nadia Li Wen Lee, Jeffrey Chun Tatt Lim, Sherlly Lim, Qing Cheng, Han Chong Toh, Su Pin Choo, Suat Ying Lee, Joycelyn Jie Xin Lee, Jin Liu, Tony Kiat Hon Lim, David Tai, Joe Yeong
Summary: Tissue protein expression of CD8, PD-L1, LAG-3, and STAT1 is associated with response to immune checkpoint blockade (ICB) in hepatocellular carcinoma (HCC). High levels of LAG-3 expression are associated with shorter survival, while high proportions of LAG-3(+) and LAG-3(+)CD8(+) cells are associated with longer survival. Immunohistochemical scoring of pre-treatment levels of LAG-3 and CD8 in the tumor microenvironment may help predict ICB benefits in HCC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Martina Amato, Renato Franco, Gaetano Facchini, Raffaele Addeo, Fortunato Ciardiello, Massimiliano Berretta, Giulia Vita, Alessandro Sgambato, Sandro Pignata, Michele Caraglia, Marina Accardo, Federica Zito Marino
Summary: Microsatellite instability (MSI) is common in cancer and predicts sensitivity to immune checkpoint inhibitors. Different MSI testing methods are used in clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Nicolas Roussot, Julie Lecuelle, Lorraine Dalens, Caroline Truntzer, Francois Ghiringhelli
Summary: A novel crosstalk between immunogenic and oncometabolic pathways triggered by T cell-released interferon-gamma (IFN-gamma) has been identified. This study explores the relationship between genomic tumor FGF2 or FGF/FGF receptor (FGFR) amplification and immunotherapy response in patients with metastatic solid cancers. The results demonstrate that FGF2 genomic amplification is associated with shorter progression-free survival and overall survival in patients undergoing immune checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Genhao Zhang, Xianping Lv, Qiankun Yang, Hongchun Liu
Summary: This study found that upregulated HM13 in HCC is associated with poor prognosis, enhanced proliferation and migration potential of HCC cells. Additionally, patients with high HM13 expression might be more sensitive to immunotherapy.
Review
Oncology
Mengwei Zhang, Jinkai Liu, Qiang Xia
Summary: Immunotherapy has been proven effective in treating various types of cancer, and recent studies have shown a significant correlation between the gut microbiome and patients' response to immunotherapy. Characteristics of the gut microbiome can serve as crucial biomarkers for predicting immunotherapy response and can also be targeted to enhance immunotherapy efficacy.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Kyle Wiatrowski, Tae Hee Kim, Amanda Przespolewski
Summary: This article provides an overview of recent advancements in immunotherapy for AML, focusing on biomarkers of response. The topics covered include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, cellular therapy, and the development of predictive biomarkers for response in each class.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Sara Elena Rebuzzi, Giuseppe Luigi Banna, Veronica Murianni, Alessandra Damassi, Emilio Francesco Giunta, Filippo Fraggetta, Ugo De Giorgi, Richard Cathomas, Pasquale Rescigno, Matteo Brunelli, Giuseppe Fornarini
Summary: Despite the improved overall survival in urothelial carcinoma patients with immune checkpoint inhibitors (ICIs), only a minority of patients benefit from this treatment. There is a need to identify biomarkers to select patients who are most likely to respond to ICIs effectively.
Article
Oncology
Robyn D. Gartrell-Corrado, Andrew X. Chen, Emanuelle M. Rizk, Douglas K. Marks, Margaret H. Bogardus, Thomas D. Hart, Andrew M. Silverman, Claire-Audrey Y. Bayan, Grace G. Finkel, Luke W. Barker, Kimberly M. Komatsubara, Richard D. Carvajal, Basil A. Horst, Rui Chang, Anthea Monod, Raul Rabadan, Yvonne M. Saenger
Article
Multidisciplinary Sciences
Megan H. Trager, Emanuelle Rizk, Sharon Rose, Kuixi Zhu, Branden Lau, Benjamin T. Fullerton, Jaya Pradhan, Michael Moore, Ayush C. Srivastava, Giselle Singer, Robyn Gartrell, Rui Chang, Larisa J. Geskin, Yvonne M. Saenger, Gary Goldenberg
Summary: The study evaluated the effect of topical treatment with imiquimod on AKs patients and identified differences in inflammatory gene expression pre and post-treatment. The findings suggest potential development of biomarkers for predicting response to immune modulators and guiding therapy.
SCIENTIFIC REPORTS
(2021)
Article
Genetics & Heredity
Andrew X. Chen, Robyn D. Gartrell, Junfei Zhao, Pavan S. Upadhyayula, Wenting Zhao, Jinzhou Yuan, Hanna E. Minns, Athanassios Dovas, Jeffrey N. Bruce, Anna Lasorella, Antonio Iavarone, Peter Canoll, Peter A. Sims, Raul Rabadan
Summary: This study identified a pro-tumor subpopulation of bone marrow-derived macrophages characterized by MARCO, which is exclusively found in IDH1-wild-type glioblastomas. MARCO expression is associated with worse prognosis and mesenchymal subtype, and significantly altered during treatment with anti-PD1 checkpoint inhibitors, suggesting potential therapeutic targets for preventing their recruitment.
Review
Oncology
Mara De Martino, Oscar Padilla, Camille Daviaud, Cheng-Chia Wu, Robyn D. Gartrell, Claire Vanpouille-Box
Summary: Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis. Immunotherapy has shown limited response as monotherapy in GBM, despite advances in the field. Recent discoveries offer insight into improving immunotherapy and exploring combinations with treatments like radiation to enhance prognosis in this devastating disease.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Douglas K. Marks, John Kucharczyk, Pan Kim, Donian Chyong, Robyn D. Gartrell, Yan Lu, Hanina Hibshoosh, Hua Guo, Thomas R. Jeffry Evans, Juanita Lopez, Rebecca Kristeleit, Eileen Connolly, Yvonne Saenger, Kevin Kalinsky
Summary: Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. T-lymphocytes are the dominant immune subset in the tumor microenvironment, with higher levels detected in stroma compared to tumor. A greater density of CD3+ and CD3 + CD8+ cells, as well as closer proximity between CD3 + CD8+ and tumor cells, was observed in patients with disease control (PR + SD) compared to those with progressive disease. The study suggests an association between TIL infiltration and Eribulin-LF sensitivity, warranting further evaluation in prospective studies.
CANCER INVESTIGATION
(2021)
Meeting Abstract
Oncology
A. Reza Djavid, Benjamin T. Fullerton, Samuel W. Wang, Meghan S. Drastal, Luke W. Barker, Robyn D. Gartrell, Bethany R. Rohr, Tammie C. Ferringer, Yvonne M. Saenger
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Hong-Jian Wei, Antonios Pouliopoulos, Nina Yoh, Masih Tazhibi, Nicholas McQuillan, Xu Zhang, Luca Szalontay, Robyn Gartrell, Jovana Pavisic, Zhiguo Zhang, Neil Feldstein, Oren Becher, Stergios Zacharoulis, Elisa Konofagou, Cheng-Chia Wu
Article
Oncology
Robyn D. Gartrell, Zoe Blake, Emanuelle M. Rizk, Rolando Perez-Lorenzo, Stuart P. Weisberg, Ines Simoes, Camden Esancy, Yichun Fu, Danielle R. Davari, Luke Barker, Grace Finkel, Manas Mondal, Hanna E. Minns, Samuel W. Wang, Benjamin T. Fullerton, Francisco Lozano, Codruta Chiuzan, Basil Horst, Yvonne M. Saenger
Summary: In this study, the combination therapy of BRAFi, anti-PD1, and OncoVEX(mGMCSF) was evaluated in a murine melanoma model. The results showed that this triple combination therapy was more effective in controlling tumor growth and increasing the infiltration of CTLs while decreasing the number of Tregs in the tumor microenvironment. This study provides a rational basis for combining targeted agents, oncolytic viral therapy, and checkpoint inhibitors in the treatment of melanoma.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Pediatrics
Elise Kang, Mercedes Martinez, Hanna Moisander-Joyce, Yvonne M. Saenger, Adam D. Griesemer, Tomoaki Kato, Darrell J. Yamashiro, Helen Remotti, Robyn D. Gartrell
Summary: This case study presents a successful orthotopic liver transplantation in an adolescent with moderately differentiated non-fibrolamellar HCC who was treated with pembrolizumab, an anti-PD1 therapy. The patient showed no evidence of recurrent disease or allograft rejection 48 months post transplantation, indicating potential use of anti-PD1 therapy in liver transplant candidates.
PEDIATRIC TRANSPLANTATION
(2022)
Meeting Abstract
Oncology
Oscar Padilla, Hanna Minns, Hong-Jian Wei, Andrea Webster-Carrion, Masih Tazhibi, Nicholas McQuillan, Xu Zhang, Zhiguo Zhang, Raul Rabadan, Peter Canoll, Luca Szalontay, Jovana Pavisic, Guy Garty, Stergios Zacharoulis, Claire Vanpouille-Box, Vilas Menon, Marta Olah, Cheng-Chia Wu, Robyn Gartrell
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Robyn D. Gartrell, Thomas Enzler, Pan S. Kim, Benjamin T. Fullerton, Ladan Fazlollahi, Andrew X. Chen, Hanna E. Minns, Subha Perni, Stuart P. Weisberg, Emanuelle M. Rizk, Samuel Wang, Eun Jeong Oh, Xinzheng Guo, Codruta Chiuzan, Gulam A. Manji, Susan E. Bates, John Chabot, Beth Schrope, Michael Kluger, Jean Emond, Raul Rabadan, Donna Farber, Helen E. Remotti, David P. Horowitz, Yvonne M. Saenger
Summary: Despite complete surgical resection and intense systemic therapies, patients with pancreatic ductal adenocarcinoma (PDAC) have a poor prognosis. Immunotherapies have almost uniformly failed in the treatment of PDAC. This study found that while chemoradiation therapy (CRT) can achieve high T cell densities in PDAC compared to melanoma, the phenotype and spatial organization of T cells may limit the benefit of T cell infiltration in this immunotherapy-resistant tumor.
Article
Multidisciplinary Sciences
Shuobo Boboila, Shunpei Okochi, Debarshi Banerjee, Sunjay Barton, Cherease Street, Ariela L. Zenilman, Qi Wang, Robyn D. Gartrell, Yvonne M. Saenger, David Welch, Cheng-Chia Wu, Angela Kadenhe-Chiweshe, Darrell J. Yamashiro, Eileen P. Connolly
Summary: The combination of high-dose radiotherapy and immunotherapy can inhibit tumor growth and prolong survival in a novel syngeneic mouse model of MYCN-amplified high-risk neuroblastoma.
Article
Oncology
Kris Ann P. Schultz, Murali Chintagumpala, Jin S. Piao, Kenneth S. Chen, Robyn Gartrell, Emily L. Christison-Lagay, Jesse L. Berry, Rachana W. Shah, Theodore W. Laetsch, Childrens Oncol Grp Rare Tumor Comm
Summary: The Children's Oncology Group (COG) Rare Tumor Committee focuses on a wide range of extracranial solid tumors that are not covered by other COG disease committees. Current therapeutic trials are targeting various rare tumors such as nasopharyngeal carcinoma, adrenocortical carcinoma, and melanoma. Collaborative efforts and novel strategies are essential for advancing research and improving outcomes in these rare tumors.
PEDIATRIC BLOOD & CANCER
(2023)
Meeting Abstract
Oncology
H. J. Wei, A. Pouliopoulos, N. Yoh, M. Tazhibi, N. McQuillan, X. Zhang, L. Szalontay, R. Gartrell, P. Jovana, Z. Zhang, N. Feldstein, S. Zacharoulis, E. E. Konofagou, C. C. Wu
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Meeting Abstract
Immunology
M. Najjar, K. Halazun, M. Mondal, A. Srivastava, M. Moore, E. Rizk, R. Gartrell, H. Remotti, L. Fazlollahi, E. Verna, A. Griesemer, A. Mathur, B. Samstein, J. Emond, Y. Saenger
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
